1. Potentials and limitations of current and emerging immunotherapies

   • Uwe K. Zettl
   • Eilhard Mix

   EDITORIAL Pages: 1 - 1

2. Pathophysiology of multiple sclerosis

   • Thomas Korn

   OriginalPaper Pages: 2 - 6

3. Animal models of multiple sclerosis for the development and validation of novel therapies – potential and limitations

   • Eilhard Mix
   • Hans Meyer-Rienecker
   • Uwe K. Zettl

   OriginalPaper Pages: 7 - 14

4. Immunomodulatory treatment strategies in multiple sclerosis

   • Bernd C. Kieseier
   • Heinz Wiendl
   • Olaf Stüve

   OriginalPaper Pages: 15 - 21

5. Immunosuppression in clinical practice

   • Andrew Chan
   • Olaf Stüve
   • Nicolas von Ahsen

   OriginalPaper Pages: 22 - 27

6. Monoclonal antibodies in the therapy of multiple sclerosis

   • P. S. Rommer
   • O. Stüve
   • U. K. Zettl

   OriginalPaper Pages: 28 - 35

7. Corticosteroids and plasma exchange in multiple sclerosis

   • Hayretin Tumani

   OriginalPaper Pages: 36 - 42

8. Stem cell transplantation in multiple sclerosis

   • Sven Schippling
   • Christoph Heesen
   • Roland Martin

   OriginalPaper Pages: 43 - 47

9. Monitoring of multiple sclerosis immunotherapy

   • Robert H. Goertsches
   • Michael Hecker
   • Uwe K. Zettl

   OriginalPaper Pages: 48 - 57

10. α4-Integrin antagonism with natalizumab

    • Olaf Stüve
    • Ralf Gold
    • Bernd C. Kieseier

    OriginalPaper Pages: 58 - 65

11. Clinical trials in multiple sclerosis: Current and future requirements – potential pitfalls

    • P. Rieckmann

    OriginalPaper Pages: 66 - 68

12. Isolated, relapsing and progressive demyelinating diseases of the central nervous system

    • Axel Petzold

    OriginalPaper Pages: 69 - 76

13. Neuroprotection and neuroregeneration in multiple sclerosis

    • Martin Stangel

    OriginalPaper Pages: 77 - 81

14. Complementary and alternative medicine in multiple sclerosis

    • Annett Apel-Neu
    • U. K. Zettl

    OriginalPaper Pages: 82 - 86

15. Compliance, adherence, and the treatment of multiple sclerosis

    • Thomas Klauer
    • Uwe K. Zettl

    OriginalPaper Pages: 87 - 92

16. Recent clinical trials and future therapies

    • Sven G. Meuth
    • Christoph Kleinschnitz
    • Heinz Wiendl

    OriginalPaper Pages: 93 - 96

17. What can we learn from failed clinical trials in multiple sclerosis?

    • Tjalf Ziemssen

    OriginalPaper Pages: 97 - 101

18. National MS registries

    • Peter Flachenecker
    • Kristin Stuke

    OriginalPaper Pages: 102 - 108

19. Cerebral MRI lesions and anti-tumor necrosis factor-alpha therapy

    • Alexander Winkelmann
    • Robert Patejdl
    • Uwe Klaus Zettl

    OriginalPaper Pages: 109 - 114

20. Muscle rupture caused by exacerbated spasticity in a patient with multiple sclerosis

    • Robert Patejdl
    • Alexander Winkelmann
    • Uwe Klaus Zettl

    OriginalPaper Pages: 115 - 118

21. Paediatric multiple sclerosis: The experience of the German Centre for Multiple Sclerosis in Childhood and Adolescence

    • Wiebke Stark*
    • Peter Huppke*
    • Jutta Gärtner

    OriginalPaper Pages: 119 - 122

22. Diagnostic algorithm for the differentiation of leukodystrophies in early MS

    • Wolfgang Köhler

    OriginalPaper Pages: 123 - 126